This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

58/100

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Risk genes beyond APOE

Topic: Amyloid, tau and blood-test diagnosis

Less-invasive biomarkers for early Alzheimer disease (AD) are urgently needed. The present study aimed to establish a panel of plasma proteins that accurately distinguishes early AD from physiological aging and to compare the findings with previous reports. Fifty-eight healthy controls (CON) and 109 patients with AD dementia were randomly split into a training (40%) and a test (60%) sample. Significant proteins to differentiate between the CON and AD dementia groups were identified in a comprehensive panel of 107 plasma analytes in the training sample; the accuracy in differentiating these 2 groups was explored in the test sample. A set of 5 plasma proteins was identified, which differentiated between the CON group and the AD dementia group with a sensitivity of 89.36% and a specificity of 79.17%. A biological pathway analysis showed that 4 of 5 proteins belonged to a common network with amyloid precursor protein and tau. Apolipoprotein E was the only protein that was both significant in the present report and in a previous proteomic study. The study provides a piece of evidence in support of the feasibility of a blood-based biomarker approach in AD diagnostics; however, further research is required because of issues with replicability.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Guo, L. H., Alexopoulos, P., Wagenpfeil, S., Kurz, A., Perneczky, R., & Alzheimer’s Disease Neuroimaging Initiative. (2013). Plasma proteomics for the identification of Alzheimer disease. Alzheimer disease and associated disorders. https://doi.org/10.1097/wad.0b013e31827b60d2

Vancouver

Guo LH, Alexopoulos P, Wagenpfeil S, Kurz A, Perneczky R, Alzheimer’s Disease Neuroimaging Initiative. Plasma proteomics for the identification of Alzheimer disease. Alzheimer disease and associated disorders. 2013. doi:10.1097/wad.0b013e31827b60d2. PMID: 23314060.

BibTeX

@article{guo2013-23314060,
  author  = {Guo, L. H. and Alexopoulos, P. and Wagenpfeil, S. and Kurz, A. and Perneczky, R. and {Alzheimer’s Disease Neuroimaging Initiative}},
  title   = {{Plasma proteomics for the identification of Alzheimer disease}},
  journal = {Alzheimer disease and associated disorders},
  year    = {2013},
  doi     = {10.1097/wad.0b013e31827b60d2},
  pmid    = {23314060},
  url     = {https://doi.org/10.1097/wad.0b013e31827b60d2}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Significant proteins to differentiate between the CON and AD dementia groups were identified in a comprehensive panel of 107 plasma analytes in the training sample; the accuracy in differentiating these 2 groups was explored in the test sample.
A biological pathway analysis showed that 4 of 5 proteins belonged to a common network with amyloid precursor protein and tau.
Apolipoprotein E was the only protein that was both significant in the present report and in a previous proteomic study.

Why it matters

Researchers compared 107 blood plasma markers in fifty-eight healthy older people and 109 people with Alzheimer's dementia and found a set of 5 proteins that told the groups apart with 89.36% sensitivity and 79.17% specificity. Apolipoprotein E was the only protein that also stood out in an earlier proteomic study. The authors see this as support for a blood test approach to diagnosis, but stress that replicability issues mean more research is needed.

New to this subject? Start with our plain-English guide: Genetics →

Study details

Study designrandomized controlled trial
Participants109
Effect size89.36%; 79.17%
Evidence strengthLow

How this study scored 58/100

Published in a peer-reviewed journal, and it is a randomized controlled trial.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Alzheimer disease and associated disorders)
Journal's citation record	1 / 4	Alzheimer Disease & Associated Disorders: journal h-index 131 (OpenAlex, 2026-10-29)
Study design	11 / 12	A randomized controlled trial
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	1 / 5	2013 — within 20 year(s) of the newest study here
Sample size	2 / 4	109 participants
Effect reported	2 / 3	Effect reported as a number, without an interval or test
Studied in people	3 / 3	Studied in people (participant count stated)
Randomized / blinded	1 / 2	Randomized (as stated in the record)
Times cited	4 / 7	Cited 56 times (OpenAlex, 2026-10-10)
Citations per year	2 / 5	3.7 citations a year over 15 year(s) since 2013
Impact for its field and year	3 / 6	Cited 3.6× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	0 / 6	No other study in this library cites it
Still being cited	1 / 4	Cited 7 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	3 / 4	Last-listed author Robert Perneczky: h-index 73 (OpenAlex, whole career)
Institution's track record	2 / 3	Imperial College London: institution h-index 1,744 (OpenAlex)
Multicenter collaboration	2 / 3	OpenAlex lists 4 institution(s) in 3 countries
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 23314060)
Free to read	0 / 2	Behind a paywall — scores zero
Total	58 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Risk genes beyond APOE

Also in Risk genes beyond APOE

105 studies in the library are filed under Risk genes beyond APOE with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Risk genes beyond APOE hub.

Similar studies

More on Risk genes beyond APOE

See all studies in Risk genes beyond APOE →